2026-04-14T16:00:39Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/63492025-01-10T13:38:10Zcom_10324_1134com_10324_931com_10324_894col_10324_1213

Orozco, Lluis Munar, Anna Soler, Robert Alberca Zaballos, María Mercedes Soler, Francesc Huguet, Marina Sentís, Joan Sánchez García, Ana María de los Ángeles García-Sancho Martín, Francisco Javier 2014-09-30T17:38:47Z 2015-09-30T23:40:08Z 2014 Transplantation, Junio 2014, vol. 97, n. 11, p. 66-68 0041-1337 http://uvadoc.uva.es/handle/10324/6349 10.1097/TP.0000000000000167 66 11 68 Transplantation 97 Osteoarthritis is the most prevalent joint disease and a frequent cause of joint pain, functional loss, and disability (1). Osteoarthritis often becomes chronic, and conventional treatments have demonstrated only modest clinical benefits, without lesion reversal (2). Cellbased therapies have shown encouraging results in both animal studies and a few human case reports.We have recently published the results of a pilot clinical trial designed to assess the feasibility and safety of osteoarthritis treatment with bone marrowYderived mesenchymal stromal cells (MSCs) in 12 patients with chronic knee pain unresponsive to conservative treatments and radiologic evidence of osteoarthritis (3). The patients were treated with autologous expanded bone marrow MSCs by intraarticular injection (40 106 cells), and clinical outcomes, including evaluations of pain, disability, and quality of life, were followed up for 1 year. Articular cartilage quality was assessed by quantitative magnetic resonance imaging (MRI) T2 mapping (3). eng info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-nd/4.0/ Attribution-NonCommercial-NoDerivatives 4.0 International Osteoartritis - Tratamiento Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stem Cells: Two-Year Follow-up Results info:eu-repo/semantics/article